Snapshot date: 2026-10-18 · Built: 2026-10-18T22:30:45+00:00 · Publication status: REVIEW

COMPANY RESEARCH

NEOGEN CORP

NEOG · United States · Healthcare

INSIDER SIGNAL

Insider activity score：40.4 / 100

1 insiders · 2 purchase events · $10k net purchases

US #834 · United States #834

WHY THIS SIGNAL?

Score anatomy

Each bar shows the contribution to the current score; the weights and formula stay unchanged.

Cluster+7.0 / 35

How many distinct insiders bought in the cluster

Purchase size+1.8 / 25

Purchase value relative to company size and liquidity

Role+7.0 / 20

The seniority and relevance of participating insiders

Recency+8.6 / 10

How recently the purchases occurred

Conviction+10.0 / 10

How clearly buying stands out from other activity

What is holding the score back?

⚠ Buyer breadth is moderate · fewer than 4 distinct filers
⚠ Purchase size is modest relative to the model scale
⚠ Insider role contributes less on the current role scale
✓ Recent activity · latest purchase 2026-10-09

The role contribution follows the US model's seniority ladder.

BUYING PROFILE

2 events · 1 insiders · 180d

Cluster 0%Repeat 100%Independent 0%Large 0%

Percentages are mutually exclusive and sum to 100%.

Buying concentration

100%

Largest buyer：Nassif Mikheal · 10k USD
Gross qualified purchase transaction-line value：10k USD

The headline $ total is net buying for the screen; this module uses gross qualified purchase transaction-line values in the filing currency, so the amounts can differ. The current 15-day buyer-breadth input counts distinct buyers; value concentration is disclosed separately here.

This is a ranking under the current US screening rules—not a probability of gain, return forecast, or buy recommendation.

Key purchase quotes (filing currency)

Filer	Price per unit	Trade date
Nassif Mikheal	11.95 USD	Oct 9, 2026
Nassif Mikheal	11.81 USD	Aug 4, 2026

Model details

Cluster breakdown (does not change the score)

15-day buyer breadth (count): 1 distinct reported filers
Peak time window: 2026-08-04 to 2026-08-04
Current breadth input: 0.200 (capped at 4+ buyers)
Buyer independence: Not yet measured; related-party fields are not cross-market comparable

What the filings show

🟢 Recent eligible purchase
Nassif Mikheal · 6k USD · Price 11.95 USD · Oct 9, 2026
🟢 Eligible purchase
Nassif Mikheal · 4k USD · Price 11.81 USD · Aug 4, 2026
🔴 21 other transaction line(s) are not counted as discretionary-buying evidence; 0 have zero price

Insider vs stock price

2 purchase day(s), 2 purchase line(s) in the 180-day window.

Daily close (USD)Day with an insider purchase

Markers sit on the closing price of the transaction day. They show when insiders traded, not the price they paid or received. "Since" compares that day's close with the last close shown; it is what happened at this company, not a forecast.

If you had followed the purchase

Each row starts on the first close on or after the day a purchase was made public, the earliest a reader could have acted, and ends on the last close shown above.

Amount put in (USD)

Made public	Insiders	In this stock, now	In the median peer stock, now	Difference
2026-08-06	1	1,086 +8.6%	922 −7.8%	+164 +16.4 pts
2026-10-09	1	1,035 +3.5%	995 −0.5%	+41 +4.1 pts

2 of 2 disclosure day(s) ended ahead of the median peer stock.

Close to close, before costs, taxes, dividends and currency moves. The peer is the median of the other stocks on the same exchange for which this site holds prices (151 here), not an index. This is what happened, not a forecast: across all purchases on this site the typical gap is close to zero.

Insider timeline

One insider bought, 2 times, the latest (9 Oct). The share closed at 11.85 that day and at 12.27 most recently (+3.5%).

Tap an item for what it means.

●A purchase: the bigger the dot, the more was bought

Each dot is one insider's purchases on one day. The dot's area follows the amount: the largest purchase here gets the largest dot. Hold the pointer over a dot to see the date and the amount.

Blue line: this share's price, +30.3% over these six months

The closing price of each day, from 9.42 on 2026-04-21 to 12.27 on 2026-10-15. The line has no scale; read it for high and low: a dot on a low stretch was bought cheaply, a dot on a high stretch was not.

Dashed line: the typical stock on the same exchange, −11.3%

Taken from the 1230 other stocks on the same exchange that this site holds prices for. Each is measured from the first day of the window, and every day the middle one is drawn. It starts where the blue line starts, so the gap between the two is the difference: this share +30.3%, the typical one −11.3%, 41.5 points ahead. It is not an index and not a comparison within one industry.

▂Grey bars: companies across United States disclosing purchases each week

A taller bar is a week in which more companies disclosed insider purchases.

This company: insiders buying per month, last 12 months

1Nov

Dec

1Jan

1Feb

Mar

Apr

May

Jun

Jul

1Aug

Sep

1Oct

Darker bars are inside the 180-day window above.

Who traded

Insider	Role	Purchases	Sales	Bought	First purchase	Share price since
Nassif Mikheal	CEO / chair	2	—	10.4k USD	2026-08-04	+3.9%

Why this score? · Model details

Priority = 100 × Σ(fixed weight × 0–1 rule-based input)

Factor	Weight	This company input	Point contribution
15-day buyer breadth (count)	35%	0.200	7.0
Qualified-buy size	25%	0.071	1.8
Role informativeness (inverted)	20%	0.650	13.0
Recency	10%	0.861	8.6
Buy/sell conviction	10%	1.000	10.0

This is a heuristic ordering under the current rules, not a calibrated return forecast. It explains why candidates rank differently; the public-filing evidence and data limits are shown below.

BULL VS BEAR

Two readings of this buying

The same filings, read two ways. Each line is a fact stored for this company with the number behind it, and appears only when that number crosses a fixed threshold. Neither side is a forecast and no winner is declared.

Where the evidence comes from

Independent evidence does not object: the purchases themselves carry bull lines (bought in the last two weeks); share price and trading, short sellers were checked and none crosses a bear threshold. No data is held for: company results, company actions.

The insider purchases themselvesBullbought in the last two weeks Bearone buyer only, small purchases5 checked, under the threshold · 1 missing
Share price and trading2 checked, under the threshold
Short sellers2 checked, under the threshold
Company results2 missing
Company actionsno data held

Bull case · the buying is informative

The latest purchase is 9 days old (2026-10-09). The buying is current, not left over from an earlier quarter.

Bear case · discount it

Only one insider bought. A single purchase can reflect that person's own finances rather than a view on the company.
All purchases in the window total $10k: a small commitment in absolute terms.

Evidence still missing

No buyer here has 5 or more completed earlier purchases on record, so there is no track record to weigh.
The company's market value is not captured, so the purchases cannot be stated as a share of the business or of its trading volume.
No earnings, margin or cash-flow figures are captured for this company. The latest annual and interim reports are where to check whether the business is improving or deteriorating.

Checked and under the threshold: 9

Either1 insider bought in the last 180 days and 1 in the 180 days before. Bull when the number at least doubles and rises by two; bear when at least two bought before and no more buy now.
BearNo insider sale is recorded in the same 180 days.
BearThe share price changed +33% over six months (three months +19%, one month −2.2%) and stands 14% below its 52-week high. Counted for the bear side from a fall of 20%.
BearOver three months the share price changed +19% and the median of 219 Healthcare companies changed −12%: ahead by 31 points. Counted for the bear side from 20 points behind.
BearNone of the 1 purchase filing ticks Form 4's 10b5-1 box.
BearOver the last 5 trading days to 2026-10-16, 54% of this stock's off-exchange volume was sold short; over the 60 days before, 61%. The market's median is 50%. This is trading volume, not a position: a market maker who sells short and covers the same day is counted, so about half of all volume is short on an ordinary day. It is shown for comparison and counts for neither side.
Bull1 of 2 purchase filings states the shares held before and after. The largest addition to an existing holding took it from 704 to 1,074 shares (+53%). Counted for the bull side from +100%, for the bear side below +1%.
BearNo insider filing in the last 180 days opened a hedge on this stock.
BearFINRA short interest on 2026-09-30 equals 2.0 days of average trading volume and 5.4% of the 218,306,034 shares outstanding, up 6.1% from the previous report. Counted for the bear side from 10 days, or from 10% of the shares outstanding.

Both columns arrange stored facts only. They do not change the insider score or the ranking and are not investment advice.

Signal history

40.4 / 100

Latest recorded score

↓ -2.3 ptssince the first recorded snapshot on 2026-09-25; 23 calendar days observed

Recorded snapshots: 18
First snapshot: 2026-09-25

There is not yet a 30-calendar-day comparison; earlier scores are not reconstructed. These are raw signal scores saved when each full scoring run completed. They describe changes in research ranking, not price performance or returns.

Why did it change?

Less than 30 days of comparable history is available, so factor movement is not yet decomposed.

Signal score history

Fixed 0–100 scale; dates are spaced by calendar time.

Recent recorded points

Sep 25, 202642.7
Oct 2, 202642.2
Oct 6, 202642.0
Oct 13, 202641.1
Oct 18, 202640.4

View all recorded scores

Snapshot date	Signal score
2026-09-25	42.7
2026-09-29	42.4
2026-09-30	42.4
2026-10-01	42.3
2026-10-02	42.2
2026-10-03	42.2
2026-10-04	42.1
2026-10-05	42.1
2026-10-06	42.0
2026-10-07	42.0
2026-10-08	42.3
2026-10-09	41.2
2026-10-12	41.3
2026-10-13	41.1
2026-10-14	41.0
2026-10-15	40.8
2026-10-16	40.7
2026-10-18	40.4

Sector context

Healthcare

Buying breadth: 4.1% (42 / 1,029 issuers)
Sector rank: #8 / 13

This is sector-level research context. It does not affect the Insider Signal or ranking.

View US sector research →

Insider profile outcomes

Historical performance following insider filings. The company role is translated below each name while preserving the original title.

Excess return = stock return − S&P 500 ETF (SPY adjusted close) return over the same period.
Hit rate = completed events with positive excess return ÷ total completed events.
Price coverage = valid point-in-time prices ÷ events mature enough for that period.
Returns start on the first shared trading session on or after publication.
Small-sample rule: n<5 is shown for transparency and is not scored.

Events are disclosure-level observations; related disclosures published on the same date may share a return path and may not be statistically independent. This research enrichment does not affect the insider score or ranking.

Nassif MikhealCEO5 completed 20D event(s)

Period	Completed events	Price coverage	Hit rate	Median excess return	Average excess return	Worst excess return
5D	5Developing evidence	83.3% (5/6)	80.0% (4/5)	+3.7%	+3.4%	-0.3%
20D	5Developing evidence	100.0% (5/5)	60.0% (3/5)	+2.4%	+1.9%	-13.9%
60D	4Small sample	100.0% (4/4)	50.0% (2/4)	-7.2%	+5.0%	-29.9%
120D	4Small sample	100.0% (4/4)	25.0% (1/4)	-7.3%	+1.0%	-15.7%

First purchase in 12M

1/6

Large purchase ≥ $100k

0/6

Cluster buying · 15D

0/6

Buying the dip · ≥20% below prior 52W high

2/6

Routine / opportunistic

Not classifiable

BOREL JAMES CDirector2 completed 20D event(s)

Period	Completed events	Price coverage	Hit rate	Median excess return	Average excess return	Worst excess return
5D	2Small sample	100.0% (2/2)	50.0% (1/2)	+2.7%	+2.7%	-3.1%
20D	2Small sample	100.0% (2/2)	100.0% (2/2)	+12.3%	+12.3%	+12.3%
60D	2Small sample	100.0% (2/2)	0.0% (0/2)	-18.1%	-18.1%	-18.8%
120D	2Small sample	100.0% (2/2)	0.0% (0/2)	-6.8%	-6.8%	-7.9%

First purchase in 12M

0/1

Large purchase ≥ $100k

2/2

Cluster buying · 15D

2/2

Buying the dip · ≥20% below prior 52W high

2/2

Routine / opportunistic

Not classifiable

ADENT JOHN EDWARDCEO1 completed 20D event(s)

Period	Completed events	Price coverage	Hit rate	Median excess return	Average excess return	Worst excess return
5D	1Small sample	100.0% (1/1)	0.0% (0/1)	-3.9%	-3.9%	-3.9%
20D	1Small sample	100.0% (1/1)	0.0% (0/1)	-18.3%	-18.3%	-18.3%
60D	1Small sample	100.0% (1/1)	0.0% (0/1)	-44.8%	-44.8%	-44.8%
120D	1Small sample	100.0% (1/1)	0.0% (0/1)	-59.6%	-59.6%	-59.6%

First purchase in 12M

Not classifiable

Large purchase ≥ $100k

1/1

Cluster buying · 15D

1/1

Buying the dip · ≥20% below prior 52W high

1/1

Routine / opportunistic

Not classifiable

Signal outcomes

Calculated from immutable US ranking snapshots; excess return is stock return minus SPY return. Newly saved snapshots remain pending until each forward horizon matures. This never affects the US score.

Horizon	Status	Result
5D	4 completed	-9.3% median
20D	Awaiting maturity	—
60D	Awaiting maturity	—
120D	Awaiting maturity	—

Market context

PRICE PERFORMANCE

-2.2%

+19.5%

+32.8%

12M

+107.6%

VOLATILITY & LIQUIDITY

Volatility: 62.0%
Beta: —
Avg daily volume: $39.2M

VALUATION

Market cap: —
P/E: —

FUNDAMENTALS

Profit margin: —
ROE: —
Industry: —

Prices to 15 Oct 2026: OpenBB/yfinance; volume from price cache (yfinance). It does not affect the insider score or rank.

Insiders' buying price vs the latest close

Insiders paid 10.73 USD a share on average (7 purchase lines, 1 buyer, 2025-11-03 – 2026-10-09). The close on 2026-10-15 was 14.4% above that price.

The latest purchase (2026-10-09) was at 11.95 USD; the close was 2.7% above that price.

Prices paid are weighted by shares and taken from the filings; dividends are not counted. Not scored.

Buying size vs market trading

Complete price and volume history is not yet available.

Market-data coverage: 0 verified sessions · Latest session: — · Ratio status: Unavailable

Traded value is estimated as close × shares traded, in major currency units. Includes disclosed qualifying purchases; disclosures may lag. Contractual or planned acquisitions are not necessarily discretionary. Ratios describe relative trading size, not market participation or score contributions.

Latest news

Neogen Announces First-Quarter Earnings Release DateBusiness Wire · wire · highrecent US news

News is reader context only; it does not change the score or inclusion.

Regulatory filings

Insider filing announcement · published 2026-10-09 · trade date 2026-10-09
Insider filing announcement · published 2026-10-02 · trade date 2026-10-01
Insider filing announcement · published 2026-10-02 · trade date 2026-10-01

Unfold all 52 filings

Insider filing announcement · published 2026-10-09 · trade date 2026-10-09
Insider filing announcement · published 2026-10-02 · trade date 2026-10-01
Insider filing announcement · published 2026-10-02 · trade date 2026-10-01
Insider filing announcement · published 2026-10-02 · trade date 2026-10-01
Insider filing announcement · published 2026-10-02 · trade date 2026-10-01
Insider filing announcement · published 2026-10-02 · trade date 2026-10-01
Insider filing announcement · published 2026-10-02 · trade date 2026-10-01
Insider filing announcement · published 2026-10-02 · trade date 2026-10-01
Insider filing announcement · published 2026-10-02 · trade date 2026-10-01
Insider filing announcement · published 2026-08-20 · trade date 2026-08-19
Insider filing announcement · published 2026-08-20 · trade date 2026-08-19
Insider filing announcement · published 2026-08-14 · trade date 2026-08-14
Insider filing announcement · published 2026-08-14 · trade date 2026-08-14
Insider filing announcement · published 2026-08-14 · trade date 2026-08-14
Insider filing announcement · published 2026-08-14 · trade date 2026-08-14
Insider filing announcement · published 2026-08-14 · trade date 2026-08-14
Insider filing announcement · published 2026-08-06 · trade date 2026-08-04
Insider filing announcement · published 2026-06-04 · trade date 2026-06-03
Insider filing announcement · published 2026-05-19 · trade date 2026-05-18
Insider filing announcement · published 2026-05-05 · trade date 2026-05-04
Insider filing announcement · published 2026-05-04 · trade date 2026-05-01
Insider filing announcement · published 2026-02-17 · trade date 2026-02-17
Insider filing announcement · published 2026-02-02 · trade date 2026-02-02
Insider filing announcement · published 2026-01-29 · trade date 2026-01-07
Insider filing announcement · published 2026-01-26 · trade date 2026-01-07
Insider filing announcement · published 2026-01-16 · trade date 2026-01-16
Insider filing announcement · published 2025-12-02 · trade date 2025-12-01
Insider filing announcement · published 2025-11-07 · trade date 2025-11-03
Insider filing announcement · published 2025-11-05 · trade date 2025-11-03
Insider filing announcement · published 2025-10-29 · trade date 2025-10-27
Insider filing announcement · published 2025-10-29 · trade date 2025-10-27
Insider filing announcement · published 2025-10-29 · trade date 2025-10-27
Insider filing announcement · published 2025-10-29 · trade date 2025-10-27
Insider filing announcement · published 2025-10-28 · trade date 2025-10-27
Insider filing announcement · published 2025-10-28 · trade date 2025-10-27
Insider filing announcement · published 2025-10-28 · trade date 2025-10-27
Insider filing announcement · published 2025-10-28 · trade date 2025-10-27
Insider filing announcement · published 2025-10-28 · trade date 2025-10-27
Insider filing announcement · published 2025-10-28 · trade date 2025-10-27
Insider filing announcement · published 2025-10-28 · trade date 2025-10-27
Insider filing announcement · published 2025-10-28 · trade date 2025-10-27
Insider filing announcement · published 2025-10-28 · trade date 2025-10-27
Insider filing announcement · published 2025-10-28 · trade date 2025-10-27
Insider filing announcement · published 2025-10-28 · trade date 2025-10-24
Insider filing announcement · published 2025-10-27 · trade date 2025-10-23
Insider filing announcement · published 2025-10-27 · trade date 2025-10-23
Insider filing announcement · published 2025-10-27 · trade date 2025-10-23
Insider filing announcement · published 2025-10-27 · trade date 2025-10-23
Insider filing announcement · published 2025-10-27 · trade date 2025-10-23
Insider filing announcement · published 2025-10-27 · trade date 2025-10-23
Insider filing announcement · published 2025-10-27 · trade date 2025-10-23
Insider filing announcement · published 2025-10-27 · trade date 2025-10-23

Results and insider purchases

Results (8-K)	Bought within 5 sessions	Bought within 20 sessions
2026-10-0616:05 ET · after the closeFirst session 2026-10-07	1 · $6.0KNassif Mikheal	1 · $6.0KNassif Mikheal8/20 sessions so far
2026-07-3007:01 ET · before the open	1 · $4.4KNassif Mikheal	1 · $4.4KNassif Mikheal
2026-04-0907:01 ET · before the open	None	None
2026-01-0807:03 ET · before the open	None	1 · $1.8KNassif Mikheal

Results dates are the company's 8-K filings to the SEC under Item 2.02 (results of operations); one filed after the close counts from the next session. Purchases are open-market buys reported on Form 4 (code P), by trade date; a Form 4 can arrive two business days after the trade, so the latest days can still fill in. Facts only; this does not change the score or rank.

Ownership and trading-plan context

Direct / indirect ownership	Direct, Indirect
10b5-1 filing evidence	Not declared in filing field
Evidence retrieved	2026-10-12T22:28:41+00:00

These are accession-level filing fields. Unavailable means the evidence was not fetched or parsed; it is never inferred as “No” and does not adjust the US score.

Filing evidence

These are underlying national-feed records from the 365-day window ending on the saved ranking snapshot. The score uses only the latest 180 days; older qualifying equity purchases remain visible for audit but do not enter the current score. The original filer, role, transaction classification, instrument, price, volume, value and source fields are retained. The first three rows are shown; remaining records can be unfolded for audit. Other transaction types are retained but excluded from the score.

Excluded transactions & classification

6 qualifying purchase disclosure(s) · 7 transaction line(s)

Nov 3, 2025Open market purchase

Nassif Mikheal · CEO

Common Shares · 177.0 shares × 6.25 USD · 1106.25 USD

Open filing

Feb 17, 2026Open market purchase

Nassif Mikheal · CEO

Common Stock · 23.0 shares × 10.94 USD · 251.61999999999998 USD

Open filing

Feb 2, 2026Open market purchase

Nassif Mikheal · CEO

Common Stock · 24.0 shares × 10.0 USD · 240.0 USD

Open filing

Unfold all 4 remaining filing row(s)

Transaction date	Published	Filer	Role	Transaction	Instrument	Price (local currency)	Quote currency	Volume	Reported value (local currency)	Source
2026-01-26	2026-02-02	Nassif Mikheal	CEO	Open market purchase	Common Stock	9.86 USD	USD	25.0	246.5 USD	Open filing
2026-01-16	2026-01-16	Nassif Mikheal	CEO	Open market purchase	Common Shares	9.33 USD	USD	137.0	1278.21 USD	Open filing
2026-08-04	2026-08-06	Nassif Mikheal	CEO	Open market purchase	Common Stock	11.81 USD	USD	370.0	4369.7 USD	Open filing
2026-10-09	2026-10-09	Nassif Mikheal	CEO	Open market purchase	Common Stock	11.95 USD	USD	505	6034.75 USD	Open filing

Showing 7 of 7 matching raw-feed row(s) from the current 365-day research window. Prices and reported values remain in the filing currency and its major unit (for example, UK pence are parsed as GBP). The screen-level $ aggregate is separately FX-normalised for research ranking, not a trade-date conversion.

Other disclosed transactions · excluded from score

View 53 other transaction(s)

Dec 1, 2025Shares withheld for tax or exercise price

Naemura David H. · Former CFO

Common Stock · 3548.0 shares × 5.98 USD · 21217.04 USD

Open filing

Dec 1, 2025Exercise of derivative security

Naemura David H. · Former CFO

Common Stock · 12912.0 shares × 5.98 USD · 77213.76000000001 USD

Open filing

Nov 3, 2025Grant or award

Riggsbee Richard Bryan · CFO

Common Stock · 178855.0 shares × 6.29 USD · 1124997.95 USD

Open filing

Unfold all 50 remaining filing row(s)

Transaction date	Published	Filer	Role	Transaction	Instrument	Price (local currency)	Quote currency	Volume	Reported value (local currency)	Source
2025-10-27	2025-10-29	BOREL JAMES C	Director	Exercise of derivative security	Common Stock	6.19 USD	USD	1777.0	10999.630000000001 USD	Open filing
2025-10-27	2025-10-29	CAPELLO JEFFREY D	Director	Exercise of derivative security	Common Stock	6.19 USD	USD	1777.0	10999.630000000001 USD	Open filing
2025-10-27	2025-10-29	Green Ronald D	Director	Exercise of derivative security	Common Stock	6.19 USD	USD	1777.0	10999.630000000001 USD	Open filing
2025-10-27	2025-10-29	Gupta Aashima	Director	Exercise of derivative security	Common Stock	6.19 USD	USD	1777.0	10999.630000000001 USD	Open filing
2025-10-27	2025-10-28	RODRIGUEZ RAFAEL A	Director	Exercise of derivative security	Common Stock	6.19 USD	USD	1777.0	10999.630000000001 USD	Open filing
2025-10-27	2025-10-28	Tobin James P	Director	Exercise of derivative security	Common Stock	6.19 USD	USD	1777.0	10999.630000000001 USD	Open filing
2025-10-27	2025-10-28	Woteki Catherine E	Director	Exercise of derivative security	Common Stock	6.19 USD	USD	1777.0	10999.630000000001 USD	Open filing
2025-10-27	2025-10-28	Rocklin Amy M	Chief Legal Officer	Shares withheld for tax or exercise price	Common Stock	6.19 USD	USD	2085.0	12906.150000000001 USD	Open filing
2025-10-27	2025-10-28	Rocklin Amy M	Chief Legal Officer	Exercise of derivative security	Common Stock	6.19 USD	USD	9474.0	58644.060000000005 USD	Open filing
2025-10-27	2025-10-28	Naemura David H.	Chief Financial Officer	Exercise of derivative security	Common Stock	6.19 USD	USD	15504.0	95969.76000000001 USD	Open filing
2025-10-27	2025-10-28	Naemura David H.	Chief Financial Officer	Shares withheld for tax or exercise price	Common Stock	6.19 USD	USD	4261.0	26375.59 USD	Open filing
2025-10-27	2025-10-28	Jones Douglas Edward	Former COO	Shares withheld for tax or exercise price	Common Stock	6.19 USD	USD	3481.0	21547.390000000003 USD	Open filing
2025-10-27	2025-10-28	Jones Douglas Edward	Former COO	Exercise of derivative security	Common Stock	6.19 USD	USD	15504.0	95969.76000000001 USD	Open filing
2025-10-27	2025-10-28	ADENT JOHN EDWARD	Former CEO	Shares withheld for tax or exercise price	Common Stock	6.19 USD	USD	8527.0	52782.130000000005 USD	Open filing
2025-10-27	2025-10-28	ADENT JOHN EDWARD	Former CEO	Exercise of derivative security	Common Stock	6.19 USD	USD	38759.0	239918.21000000002 USD	Open filing
2025-10-27	2025-10-28	BOEHM WILLIAM T	Director	Exercise of derivative security	Common Stock	6.07 USD	USD	3553.0	21566.710000000003 USD	Open filing
2025-10-27	2025-10-28	CAPELLO JEFFREY D	Director	Exercise of derivative security	Common Stock	6.19 USD	USD	2025.0	12534.75 USD	Open filing
2025-10-27	2025-10-28	BOREL JAMES C	Director	Exercise of derivative security	Common Stock	6.19 USD	USD	2025.0	12534.75 USD	Open filing
2025-10-24	2025-10-28	Pelossof Avi	Director	Grant or award	Common Stock	6.19 USD	USD	19386.0	119999.34000000001 USD	Open filing
2025-10-23	2025-10-27	Woteki Catherine E	Director	Grant or award	Common Stock	6.07 USD	USD	19769.0	119997.83 USD	Open filing
2025-10-23	2025-10-27	Wainer Andrea F	Director	Grant or award	Common Stock	6.07 USD	USD	19769.0	119997.83 USD	Open filing
2025-10-23	2025-10-27	RODRIGUEZ RAFAEL A	Director	Grant or award	Common Stock	6.07 USD	USD	19769.0	119997.83 USD	Open filing
2025-10-23	2025-10-27	Gupta Aashima	Director	Grant or award	Common Stock	6.07 USD	USD	19769.0	119997.83 USD	Open filing
2025-10-23	2025-10-27	Green Ronald D	Director	Grant or award	Common Stock	6.07 USD	USD	19769.0	119997.83 USD	Open filing
2025-10-23	2025-10-27	CAPELLO JEFFREY D	Director	Grant or award	Common Stock	6.07 USD	USD	19769.0	119997.83 USD	Open filing
2025-10-23	2025-10-27	Bernard Thierry	Director	Grant or award	Common Stock	6.07 USD	USD	19769.0	119997.83 USD	Open filing
2025-10-23	2025-10-27	BOREL JAMES C	Director	Grant or award	Common Stock	6.07 USD	USD	19769.0	119997.83 USD	Open filing
2026-01-07	2026-01-29	Ranalli Tamara A.	Senior Vice President	Grant or award	Common Stock	7.38 USD	USD	50813.0	374999.94 USD	Open filing
2026-01-07	2026-01-26	Ranalli Tamara A.	Senior Vice President	Grant or award	Common Stock	7.38 USD	USD	50813.0	374999.94 USD	Open filing
2026-06-03	2026-06-04	Moylan John Patrick	Chief Accounting Officer	Shares withheld for tax or exercise price	Restricted Stock Units	8.75 USD	USD	2553.0	22338.75 USD	Open filing
2026-05-18	2026-05-19	Rocklin Amy M	Former Chief Legal Officer	Exercise of derivative security	Common Stock	9.29 USD	USD	35183.0	326850.06999999995 USD	Open filing
2026-05-18	2026-05-19	Rocklin Amy M	Former Chief Legal Officer	Shares withheld for tax or exercise price	Common Stock	9.29 USD	USD	10241.0	95138.88999999998 USD	Open filing
2026-05-04	2026-05-05	Moylan John Patrick	Chief Accounting Officer	Exercise of derivative security	Common Stock	9.53 USD	USD	4558.0	43437.74 USD	Open filing
2026-05-04	2026-05-05	Moylan John Patrick	Chief Accounting Officer	Shares withheld for tax or exercise price	Common Stock	9.53 USD	USD	1568.0	14943.039999999999 USD	Open filing
2026-05-01	2026-05-04	Stacey Jennifer Evans	Chief Legal Officer	Grant or award	Common Stock	9.53 USD	USD	39349.0	374995.97 USD	Open filing
2026-08-19	2026-08-20	Moylan John Patrick	Chief Accounting Officer	Shares withheld for tax or exercise price	Restricted Stock Units	11.87 USD	USD	2365.0	28072.55 USD	Open filing
2026-08-19	2026-08-20	Nassif Mikheal	CEO	Shares withheld for tax or exercise price	Restricted Stock Units	11.87 USD	USD	20397.0	242112.38999999998 USD	Open filing
2026-08-14	2026-08-14	Moylan John Patrick	Chief Accounting Officer	Grant or award	Restricted Stock Units	11.65 USD	USD	8584.0	100003.6 USD	Open filing
2026-08-14	2026-08-14	Ranalli Tamara A.	Senior Vice President	Grant or award	Common Stock	11.65 USD	USD	25751.0	299999.15 USD	Open filing
2026-08-14	2026-08-14	Stacey Jennifer Evans	Chief Legal Officer	Grant or award	Common Stock	11.65 USD	USD	38627.0	450004.55 USD	Open filing
2026-08-14	2026-08-14	Riggsbee Richard Bryan	CFO	Grant or award	Common Stock	11.65 USD	USD	51502.0	599998.3 USD	Open filing
2026-08-14	2026-08-14	Nassif Mikheal	CEO	Grant or award	Common Stock	11.65 USD	USD	141631.0	1650001.1500000001 USD	Open filing
2026-10-01	2026-10-02	BOREL JAMES C	Director	Grant or award	Restricted Stock Units	12.24 USD	USD	9804	120000.96 USD	Open filing
2026-10-01	2026-10-02	CAPELLO JEFFREY D	Director	Grant or award	Restricted Stock Units	12.24 USD	USD	9804	120000.96 USD	Open filing
2026-10-01	2026-10-02	Green Ronald D	Director	Grant or award	Restricted Stock Units	12.24 USD	USD	9804	120000.96 USD	Open filing
2026-10-01	2026-10-02	Gupta Aashima	Director	Grant or award	Restricted Stock Units	12.24 USD	USD	9804	120000.96 USD	Open filing
2026-10-01	2026-10-02	Pelossof Avi	Director	Grant or award	Restricted Stock Units	12.24 USD	USD	9804	120000.96 USD	Open filing
2026-10-01	2026-10-02	RODRIGUEZ RAFAEL A	Director	Grant or award	Restricted Stock Units	12.24 USD	USD	9804	120000.96 USD	Open filing
2026-10-01	2026-10-02	Wainer Andrea F	Director	Grant or award	Restricted Stock Units	12.24 USD	USD	9804	120000.96 USD	Open filing
2026-10-01	2026-10-02	Woteki Catherine E	Director	Grant or award	Restricted Stock Units	12.24 USD	USD	9804	120000.96 USD	Open filing

Showing 53 of 53 matching raw-feed row(s) from the current 365-day research window. Prices and reported values remain in the filing currency and its major unit (for example, UK pence are parsed as GBP). The screen-level $ aggregate is separately FX-normalised for research ranking, not a trade-date conversion.

Snapshot & identity

Snapshot date: 2026-10-18
Ticker: NEOG
ISIN: —
Sector: Healthcare
Industry: —

Company logos by Parqet

How to read Form 4 transaction codes

Code	Interpretation	Screen treatment
P	Open-market / private purchase	Buy evidence when the security is qualifying equity
S	Sale	Sell evidence when the security is qualifying equity
A	Grant / award	Context only
F	Tax-related withholding	Context only
M	Option exercise	Context only
G	Gift	Context only
J / L	Other / non-directional	Context only

P/S rows for options, warrants, compensation units and debt remain visible for audit but are excluded from equity scores and quotes.

NEOGEN CORP

WHY THIS SIGNAL?

Score anatomy

What is holding the score back?

BUYING PROFILE

Buying concentration

Key purchase quotes (filing currency)

Cluster breakdown (does not change the score)

What the filings show

Insider vs stock price

If you had followed the purchase

Insider timeline

This company: insiders buying per month, last 12 months

Who traded

Two readings of this buying

Where the evidence comes from

Bull case · the buying is informative

Bear case · discount it

Evidence still missing

Signal score history

Recent recorded points

Sector context

Insider profile outcomes

Signal outcomes

Market context

PRICE PERFORMANCE

VOLATILITY & LIQUIDITY

VALUATION

FUNDAMENTALS

Insiders' buying price vs the latest close

Buying size vs market trading

Latest news

Regulatory filings

Results and insider purchases

Ownership and trading-plan context

Filing evidence

Other disclosed transactions · excluded from score

Snapshot & identity

Share this page

How to read Form 4 transaction codes